|Bid||40.50 x 1300|
|Ask||45.50 x 1100|
|Day's Range||44.12 - 44.67|
|52 Week Range||37.43 - 45.62|
|Beta (3Y Monthly)||0.37|
|PE Ratio (TTM)||22.81|
|Forward Dividend & Yield||1.86 (4.10%)|
|1y Target Est||52.00|
Shares of French pharmaceutical giant Sanofi dipped Friday after the FDA rejected its application for a diabetes treatment created under a partnership with Lexicon Pharmaceuticals.
The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday. The decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin, should be approved as an add-on to insulin therapy. The setback comes as Sanofi works to revive declining sales from its diabetes division, and as the French drugmaker faces increasing pressure from politicians and patient advocacy groups over the rising cost of its insulin products.
Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.
The nanocap biotech company said Tuesday that additional data from a Phase 2 extension study of its NasoVAX, an intranasal influenza vaccine candidate, showed that 100 percent of the evaluated subjects remained seroprotected. The Phase 2 extension study enlisted the subjects from the highest dose group of the midstage study to evaluate the duration of immunity one year after vaccination. All eight subjects out of the 15 invited, who returned an average of 13.5 months after vaccination, remained seroprotected.
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts have set Sanofi’s (SNY) 12-month consensus target price at $52, 15.79% higher than the stock’s
Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday. Sanofi has an age limit of 65 for its CEO. Brandicourt will be 65 in February 2021.
Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.
The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.
The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs. Shares of Regeneron closed up 2.3 percent at $412.05 on Monday. The FDA first approved the drug in 2017 and it has since been launched as a treatment for adults with moderate-to-severe atopic dermatitis, or eczema, as well as a drug for some asthma patients.
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control persistent, often debilitating symptoms such as chronic itch and widespread rash.
The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs. The drug was initially approved in 2017 and has since been launched in the United States as a treatment for adults with moderate-to-severe atopic dermatitis, as well as a drug for some asthma patients.
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report PARIS, France - March 8, 2019 ...
March 8, 2019 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with severe CRSwNP often experience recurrence despite previous treatment with surgery and/or systemic corticosteroids.
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%. The company reported adjusted EPS of $4.58, a YoY